Xevinapant (Debio 1143)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Xevinapant (Debio 1143), covering 2025-10-08 to 2025-10-08. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) [Phase 3]